Lifetime Medical Costs of Knee Osteoarthritis Management in the United States: Impact of Extending Indications for Total Knee Arthroplasty
Tóm tắt
The impact of increasing utilization of total knee arthroplasty (TKA) on lifetime costs in persons with knee osteoarthritis (OA) is understudied.
We used the Osteoarthritis Policy Model to estimate total lifetime costs and TKA utilization under a range of TKA eligibility criteria among US persons with symptomatic knee OA. Current TKA utilization was estimated from the Multicenter Osteoarthritis Study and calibrated to Health Care Cost and Utilization Project data. OA treatment efficacy and toxicity were drawn from published literature. Costs in 2013 dollars were derived from Medicare reimbursement schedules and Red Book Online. Time costs were derived from published literature and the US Bureau of Labor Statistics.
Estimated average discounted (3% per year) lifetime costs for persons diagnosed with knee OA were $140,300. Direct medical costs were $129,600, with $12,400 (10%) attributable to knee OA over 28 years. OA patients spent a mean ± SD of 13 ± 10 years waiting for TKA after failing nonsurgical regimens. Under current TKA eligibility criteria, 54% of knee OA patients underwent TKA over their lifetimes. Estimated OA‐related discounted lifetime direct medical costs ranged from $12,400 (54% TKA uptake) when TKA eligibility was limited to Kellgren/Lawrence grades 3 or 4 to $16,000 (70% TKA uptake) when eligibility was expanded to include symptomatic OA with a lesser degree of structural damage.
Because of low efficacy of nonsurgical regimens, knee OA treatment–attributable costs are low, representing a small portion of all costs for OA patients. Expanding TKA eligibility increases OA‐related costs substantially for the population, underscoring the need for more effective nonoperative therapies.
Từ khóa
Tài liệu tham khảo
Gabriel SE, 1997, Direct medical costs unique to people with arthritis, J Rheumatol, 24, 719
Gabriel SE, 1995, Costs of osteoarthritis: estimates from a geographically defined population, J Rheumatol, 43, 23
MacLean CH, 1998, Costs attributable to osteoarthritis, J Rheumatol, 25, 2213
Mapel DW, 2004, Hospital, pharmacy, and outpatient costs for osteoarthritis and chronic back pain, J Rheumatol, 31, 573
US Department of Health and Human Services. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project: nationwide inpatient sample.2011. URL:http://hcupnet.ahrq.gov.
Fioravanti A, 2003, Clinical efficacy and cost‐effectiveness evidence of spa therapy in osteoarthritis: the results of “naiade” Italian project, Panminerva Med, 45, 211
Pope JE, 2004, The efficacy and cost effectiveness of n of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritis, J Rheumatol, 31, 140
US Department of Health and Human Services. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project: nationwide inpatient sample.1997. URL:http://hcupnet.ahrq.gov.
US Department of Labor. Bureau of Labor Statistics. Economic news release. Table A‐6: employment status of the civilian population by sex age and disability status not seasonally adjusted.2013. URL:http://www.bls.gov/news.release/empsit.t06.htm.
US Department of Health and Human Services. Centers for Disease Control and Prevention. Health Data Interactive. URL:http://www.cdc.gov/nchs/hdi.htm.
AriasE. National vital statistics reports: United States life tables 2009. Centers for Disease Control and Prevention. URL:http://www.cdc.gov/nchs/products/nvsr.htm#vol62.
US Department of Health and Human Services. Centers for Disease Control and Prevention. National Health Interview Survey 2010Data Release. URL:http://www.cdc.gov/nchs/nhis/nhis_2010_data_release.htm.
US Department of Health and Human Services. National Institutes of Health. Osteoarthritis Initiative. URL:http://oai.epi‐ucsf.org/datarelease/default.asp.
US Department of Health and Human Services. Centers for Disease Control and Prevention. National Health Interview Survey 2012Data Release. URL:http://www.cdc.gov/nchs/nhis/nhis_2012_data_release.htm.
National Health and Nutrition Examination Survey 2009‐2010. Hyattsville (MD): US Department of Health and Human Services/National Center for Health Statistics;2010.
Centers for Medicare & Medicaid Services. Medicare Current Beneficiary Survey.2009. URL:http://www.cms.gov/Research‐Statistics‐Data‐and‐Systems/Research/MCBS/index.html.
US Department of Labor. Bureau of Labor Statistics. Consumer Price Index. URL:http://www.bls.gov/cpi/#data.
Red Book Online. Truven Health Analytics Inc.2014. URL:http://micromedex.com/redbook.
Centers for Medicare & Medicaid Services. Medicare fee schedules.2012. URL:http://www.cms.gov/Medicare/Medicare‐Fee‐for‐Service‐Payment/PFSlookup/index.html.
Centers for Medicare & Medicaid Services. Hospital outpatient prospective payment system. URL:http://www.cms.gov/HospitalOutpatientPPS/.
Centers for Medicare & Medicaid Services. MEDPAR2011. URL:http://www.cms.gov/Research‐Statistics‐Data‐and‐Systems/Statistics‐Trends‐and‐Reports/MedicareFeeforSvcPartsAB/MEDPAR.html.
Buntin MB, 2005, Comparison of Medicare spending and outcomes for beneficiaries with lower extremity joint replacements
Mahomed NN, 2002, The importance of patient expectations in predicting functional outcomes after total joint arthroplasty, J Rheumatol, 29, 1273
Pope GC, 2004, Risk adjustment of Medicare capitation payments using the CMS‐HCC model, Health Care Financ Rev, 25, 119
The use of medicines in the United States: review of 2010. Parsippany (NJ): IMS Institute for Healthcare Informatics;2011.
US Department of Health and Human Services. Office of Inspector General. Medicaid drug price comparison: average sales price to average wholesale price.2005. URL:http://oig.hhs.gov/oei/reports/oei‐03‐05‐00200.pdf.
Yen ZS, 2004, Cost‐effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan, J Rheumatol, 31, 1797